Home・Akcijų sąrašas・Danaher Corp

Danaher Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

194.61 -1.46

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

192.43

Max

199.67

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-159M 870M
Pardavimai	314M 6.3B
P/E Sektoriaus vid.	35.027 64.641
Pelnas, tenkantis vienai akcijai	1.94
Dividendų pajamingumas	0.75
Pelno marža	13.887
Darbuotojai	58,000
EBITDA	-364M 1.1B

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+11.28% upside

Dividendai
By Acuity
Dividendų pajamingumas Sektoriaus vid.	0.75% 2.31%
Kitas uždarbis	2026-10-20
Kitas dividendų mokėjimo data	2026-10-30
Kita Ex Dividend data	2026-09-25

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-4.2B 138B
Ankstesnė atidarymo kaina	196.07
Ankstesnė uždarymo kaina	194.61

Naujienos nuotaikos

By Acuity

50%

151 / 340 reitingas Healthcare

Danaher Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-03 22:51; UTC

News

Danaher Corp appointed Julie Sawyer Montgomery as President and CEO, effective October 1, 2026. Shares are trading higher in after-market hours.

2026-07-31 23:01; UTC

Danaher Corp shares are lower in after-market trading, with no specific news identified to explain the decline amid broader market weakness.

2026-07-30 18:01; UTC

Danaher Corp. shares are lower today, fluctuating within their one-month range amid volatility influenced by the Federal Reserve's interest rate decisions.

2026-07-29 23:01; UTC

Danaher Corp shares are higher in after-market trading, reflecting a slight increase since Wednesday's close. The stock reached a recent high shortly after 5:10 PM ET.

2026-07-28 23:01; UTC

Danaher Corp shares declined in after-hours trading amid broader market losses linked to concerns over artificial intelligence spending and competition from Chinese chipmakers.

2026-07-27 23:16; UTC

Danaher Corp shares are lower in after-market trading, declining slightly since Monday's close. No specific company news has been identified to explain the movement.

2026-07-24 20:06; UTC

News

Danaher Corp shares are lower amid concerns over reduced sales growth in its biotechnology segment, despite raising full-year earnings guidance to $8.45-$8.60.

2026-07-23 10:01; UTC

Danaher Corp shares are lower in pre-market trading, continuing a decline since Wednesday's close and remaining below the 20-day moving average.

2026-07-22 22:01; UTC

Danaher Corp shares are trading lower in after-market hours, continuing a trend of six consecutive sessions finishing lower amid rising crude oil prices and market volatility.

2026-07-21 19:41; UTC

News

Social Media

Danaher Corp shares are lower after the company issued a cautious fiscal 2026 revenue growth forecast despite reporting better-than-expected second-quarter earnings and revenues.

2026-07-20 23:41; UTC

Danaher Corp shares declined in after-market trading, continuing a trend of lower finishes amid concerns over economic momentum and a drop in the leading economic index.

Akcijų palyginimas

Kainos pokytis

Danaher Corp Prognozė

Kainos tikslas

By TipRanks

11.28% į viršų

12 mėnesių prognozė

Vidutinis 219.78 USD 11.28%

Aukščiausias 240 USD

Žemiausias 195 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Danaher Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

Pirkti

Laikyti

Parduoti

Remiantis 20 analitikų, pateikusių Danaher Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

151 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.